Cardiovascular adverse events in lung cancer patients receiving immune checkpoint inhibitor therapy: An analysis of a nationwide electronic medical record data
Phase 4
- Conditions
- Patients with primary lung cancer
- Registration Number
- JPRN-UMIN000051698
- Lead Sponsor
- Sendai Kousei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with previous diagnosis of the following diseases are excluded from the analysis: Multiple myeloma BCR-ABL-positive chronic myelogenous leukemia Cervical cancer Ovarian cancer Hepatocellular carcinoma Gastric cancer Rectal cancer Colon cancer 3)Patients without a 180-day look-back period commencing at the time of first ICI treatment (study group) or at the time of the first start of predefined chemotherapy other than ICI (control group).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method